Topical Cetirizine 1% vs Minoxidil 5% Gel in Treatment of Androgenetic Alopecia
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04293822 |
|
Recruitment Status :
Not yet recruiting
First Posted : March 3, 2020
Last Update Posted : March 4, 2020
|
| Tracking Information | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| First Submitted Date ICMJE | February 21, 2020 | ||||||||
| First Posted Date ICMJE | March 3, 2020 | ||||||||
| Last Update Posted Date | March 4, 2020 | ||||||||
| Estimated Study Start Date ICMJE | June 2020 | ||||||||
| Estimated Primary Completion Date | November 2020 (Final data collection date for primary outcome measure) | ||||||||
| Current Primary Outcome Measures ICMJE |
Change of the hair density (follicles/cm²) [ Time Frame: 6 months ] Improvement of the outcomes of treatment of androgenetic alopecia with Cetirizine 1% gel in comparison to Minoxidil 5% gel in terms of proportion of hair regrowth, the hair density (follicles/cm²) .
|
||||||||
| Original Primary Outcome Measures ICMJE |
Improvement of the hair density (follicles/cm²) [ Time Frame: 6 months ] Improvement of the outcomes of treatment of androgenetic alopecia with Cetirizine 1% gel in comparison to Minoxidil 5% gel in terms of proportion of hair regrowth, the hair density (follicles/cm²) .
|
||||||||
| Change History | |||||||||
| Current Secondary Outcome Measures ICMJE |
Change of the hair diameter [ Time Frame: 6 months ] Improvement of the vellus and terminal hair diameter <0.05 mm>
|
||||||||
| Original Secondary Outcome Measures ICMJE |
Improvement of the hair diameter [ Time Frame: 6 months ] Improvement of the vellus and terminal hair diameter <0.05 mm>
|
||||||||
| Current Other Pre-specified Outcome Measures | Not Provided | ||||||||
| Original Other Pre-specified Outcome Measures | Not Provided | ||||||||
| Descriptive Information | |||||||||
| Brief Title ICMJE | Topical Cetirizine 1% vs Minoxidil 5% Gel in Treatment of Androgenetic Alopecia | ||||||||
| Official Title ICMJE | Topical Cetirizine Gel Versus Minoxidil 5% Gel in Treatment of Androgenetic Alopecia | ||||||||
| Brief Summary | Androgenetic alopecia (AGA), also known as androgenic alopecia or male pattern baldness, is the most common type of progressive hair loss. It is a polygenetic condition with variable degree of severity, age of onset, and location of hair loss. Male AGA (MAGA) is clearly an androgen-dependent condition and, although the mode of inheritance is uncertain, a genetic predisposition is observed. Regarding treatment of AGA; in most cases it's challenging and unsatisfactory. Finasteride and Minoxidil 2-5 % solution are the only US Food and Drug Administration (FDA) approved treatment options for MAGA. On the basis of hypertrichosis observed in patients treated with analogues of prostaglandin PGF2a (i.e. latanoprost used for glaucoma), it was supposed that prostaglandins would have an important role in the hair growth (Nieves et al., 2014). Multiple studies had claimed that prostaglandins are deregulated in both alopecia areata (AA) and AGA. Cetirizine, is a safe and selective second-generation histamine H1 receptor antagonist widely used. It has anti-inflammatory properties. Studies have shown cetirizine causes a significant reduction in both the inflammatory cell infiltrate and PGD2 production. The oral administration of cetirizine is commonly leads to different systemic side effects. Thus the topical formulation is expected to be an effective tool for avoiding the oral side effects as well as better targeting, but unfortunately, no topical formulation of cetirizine is available in the market till date. |
||||||||
| Detailed Description | Androgenetic alopecia (AGA), also known as androgenic alopecia or male pattern baldness, is the most common type of progressive hair loss. It is a polygenetic condition with variable degree of severity, age of onset, and location of hair loss. Hair loss typically begins with bi-temporal recession of the frontal hairline, followed by diffuse hair thinning at the vertex, and eventual complete loss of hair at the center of the vertex. The bald patch at the vertex subsequently joins the frontal receding hairline, leaving an island of hair on the frontal scalp, which finally disappears leaving hair only in the parietal and occipital zones producing the characteristic "horseshoe" pattern. Androgenetic alopecia is classified according to the Hamilton-Norwood scale into grades (from I to VII). AGA features a progressive miniaturization of the hair follicle leading to vellus transformation of terminal hair which results from an alteration in hair cycle dynamics: anagen phase duration gradually decreases and that of the telogen phase increases. As the anagen phase duration determines hair length, the new anagen hair becomes shorter, eventually leading to bald appearance. The etiology of AGA is multifactorial and polygenetic. Male AGA (MAGA) is clearly an androgen-dependent condition and, although the mode of inheritance is uncertain, a genetic predisposition is observed, while in female AGA (FAGA) the role of androgens is still uncertain. Regarding treatment of AGA; in most cases it's challenging and unsatisfactory. Finasteride and Minoxidil 2-5 % solution are the only US Food and Drug Administration (FDA) approved treatment options for MAGA. Finasteride is a type 2 5α-reductase inhibitor that decreases the conversion of testosterone to dihydrotestosterone (DHT), which is responsible for the miniaturization of the hair follicle seen in MAGA. Minoxidil is a direct arteriolar vasodilator acts by opening potassium channels. Unwanted hair growth was observed as an adverse effect in 24-100 % of patients treated by Minoxidil for hypertension. Minoxidil 2 % solution was approved in 1988, while the 5 % solution was approved in 1991, and the 5 % foam in 2016 for MAGA. On the basis of hypertrichosis observed in patients treated with analogues of prostaglandin PGF2a (i.e. latanoprost used for glaucoma), it was supposed that prostaglandins would have an important role in the hair growth. Their action is variable depending on the class they belong to: PGE and PGF2a play a generally positive role on the hair growth, while PGD2 an inhibitory role on the hair growth. Multiple studies had claimed that prostaglandins are deregulated in both alopecia areata (AA) and AGA. Garza in 2012 found elevated levels of prostaglandin D2 synthase (PTGDS) at the mRNA and protein levels in bald scalp versus haired scalp of men with AGA. Also found that the enzymatic product of PTGDS and prostaglandin D2 (PGD2) are raised in bald human scalp tissue. These results implicate that PGD2 might has a role in pathogenesis of AGA, thus suggest new receptor targets for its treatment. Cetirizine, the active carboxylic acid metabolite of hydroxyzine, is a safe and selective second-generation histamine H1 receptor antagonist widely used in daily practice. It has anti-inflammatory properties and high specific affinity for histamine H1 receptors. Studies have shown cetirizine causes a significant reduction in both the inflammatory cell infiltrate and PGD2 production, and these effects are not related to its anti-H1 activity. The oral administration of cetirizine is commonly leads to different systemic side effects as sedation, ocular dryness, tiredness and dry mouth. Thus, the topical formulation for cetirizine is expected to be a rational and effective tool for avoiding the oral side effects as well as better targeting, but unfortunately, no topical formulation of cetirizine is available in the market till date. As the stratum corneum is the main barrier for the effective topical drug application, numerous attempts have been made to enhance topical drug delivery such as lipid nanocarriers (nano-transferosomes (NTF), follicular penetration, microbubbles and microneedles. Rossi in 2018 evaluated for the first time in literature the tolerability and efficacy of topical cetirizine 1% lotion inpatients with AGA and claimed that topical cetirizine causes a significant improvement of the initial framework of AGA in both males and females and recommended further studies to allow better investigation for the role of cetirizine in AGA. To the best of the investigators knowledge the use of topical cetirizine 1% gel has not yet been tried in the therapeutic management of Egyptian males with AGA. |
||||||||
| Study Type ICMJE | Interventional | ||||||||
| Study Phase ICMJE | Phase 4 | ||||||||
| Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) Masking Description: The patients will be randomly divided into 2 groups; each group contains 30 patients. Patients in both groups will be given the treatment in identical non-labeled bottles with a code and neither the patient nor the doctor will know which treatment is given and what the code referred to. The patients will be instructed to use the treatment twice daily for 6 month duration. Primary Purpose: Treatment
|
||||||||
| Condition ICMJE | Androgenetic Alopecia | ||||||||
| Intervention ICMJE |
|
||||||||
| Study Arms ICMJE |
|
||||||||
| Publications * | Not Provided | ||||||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||
| Recruitment Information | |||||||||
| Recruitment Status ICMJE | Not yet recruiting | ||||||||
| Estimated Enrollment ICMJE |
60 | ||||||||
| Original Estimated Enrollment ICMJE | Same as current | ||||||||
| Estimated Study Completion Date ICMJE | November 2021 | ||||||||
| Estimated Primary Completion Date | November 2020 (Final data collection date for primary outcome measure) | ||||||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||||
| Sex/Gender ICMJE |
|
||||||||
| Ages ICMJE | 18 Years to 50 Years (Adult) | ||||||||
| Accepts Healthy Volunteers ICMJE | No | ||||||||
| Contacts ICMJE |
|
||||||||
| Listed Location Countries ICMJE | Egypt | ||||||||
| Removed Location Countries | |||||||||
| Administrative Information | |||||||||
| NCT Number ICMJE | NCT04293822 | ||||||||
| Other Study ID Numbers ICMJE | AssiutU Dermatology | ||||||||
| Has Data Monitoring Committee | Not Provided | ||||||||
| U.S. FDA-regulated Product |
|
||||||||
| IPD Sharing Statement ICMJE | Not Provided | ||||||||
| Responsible Party | Reham Abdalla Ibrahim, Assiut University | ||||||||
| Study Sponsor ICMJE | Assiut University | ||||||||
| Collaborators ICMJE | Not Provided | ||||||||
| Investigators ICMJE |
|
||||||||
| PRS Account | Assiut University | ||||||||
| Verification Date | March 2020 | ||||||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||||||